Documented substance use among stroke patients aged 20 to 54 increased from 4.6% in 1993–1994 to 40.2% in 2020.

Overview Debates Related claims Topics Sources

Childhood trauma leads people to develop psychosis

The proposed FY26 budget restructuring includes a $1 billion funding reduction affecting community mental health centers, suicide prevention, and substance use treatment programs.

The President's FY26 budget proposed dissolving the Substance Abuse and Mental Health Services Administration and the Health Resources and Services Administration to consolidate them into a new Administration for a Healthy America.

The Substance Abuse and Mental Health Services Administration reinstated $2 billion in mental health and substance use grants on January 14, 2026, following bipartisan pushback.

On January 13, 2026, the Substance Abuse and Mental Health Services Administration terminated hundreds of grants totaling approximately $2 billion for mental health and substance use disorder services.

Heavy alcohol use, drug use, and smoking were associated with looking biologically older in FAHR-FaceAge facial photograph analyses, with current smokers appearing older than former smokers.

More young people need to get their brain scanned

A study in BMJ Open associated childhood adversity with 60% of drug use in Wales, 57% in England, 49% of violence in Wales, and 46% in England.

Satralizumab is a humanized monoclonal antibody designed to bind to soluble and membrane-bound interleukin-6 receptors, inhibiting interleukin-6-mediated inflammatory signaling

Thyroid eye disease is an inflammatory autoimmune condition affecting an estimated 16 women and 3 men per 100,000 population, commonly occurring in people with hyperthyroidism

Satralizumab is the first and only at-home subcutaneous treatment cleared by the FDA for adults with thyroid eye disease

Prior to satralizumab's approval, the FDA approved two intravenous thyroid eye disease treatments targeting the insulin-like growth factor 1 receptor: teprotumumab in 2020 and veligrotug in June 2026

Satralizumab was initially approved by the FDA in 2020 for neuromyelitis optica spectrum disorder, a rare neuroinflammatory condition

Satralizumab can be self-administered subcutaneously by a patient or caregiver following initial training from a healthcare provider

Although satralizumab's SatraGO-1 trial failed to meet its primary efficacy endpoint at week 24, satralizumab received approval based on efficacy results from satralizumab's SatraGO-2

On October 15, 2026, the U.S. Food and Drug Administration approved satralizumab-mwge (Enspryng), developed by Genentech, for adults with thyroid eye disease

The FDA approval of satralizumab for thyroid eye disease was based on data from the global phase 3 SatraGO program, which enrolled 258 patients across 19 countries

In satralizumab's phase 3 SatraGO-2 trial of active thyroid eye disease, 52.9% of satralizumab patients achieved a proptosis response of at least 2 mm reduction (vs. 23.4% placebo) and 60.7% achieved diplopia reduction (vs. 25.8% placebo)

Roche is studying satralizumab in additional neurologic, autoimmune, and inflammatory conditions that may benefit from interleukin-6 signaling inhibition

Thyroid eye disease symptoms can include eye swelling, eyelid retraction, a constant stare, proptosis, diplopia, and pain, which can be disfiguring, debilitating, or blinding